EUVIMEDEUVIMED entdecken
Crossref

Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence ( CoE ): Survey from the ENETS lung NET task force

Anna Koumarianou, Pier Luigi Filosso, Lisa Bodei iD, Justo P Castano, Lynnette Fernandez-Cuesta, Christophe M Deroose, Matthieu Foll, Clarisse Dromain iD, Nicholas Simon Reed, Martyn Caplin, Jaume Capdevila, Jenny Falkerby und 13 weitere

Journal of Neuroendocrinology · 2024

DOI: 10.1111/jne.13412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroendocrinology, 2024. Verfasst von Anna Koumarianou und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University o…. Hauptthemen laut MEDLINE: Carcinoid Tumor, Lung Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung carcinoid tumours are neuroendocrine neoplasms originating from the bronchopulmonary tract's neuroendocrine cells, accounting for only 1%–3% of all lung cancers but 30% of all neuroendocrine tumours. The incidence of lung carcinoids, both typical and atypical, has been increasing over the years due to improved diagnostic methods and increased awareness among clinicians and pathologists. The most recent WHO classification includes a subgroup of lung carcinoids with atypical morphology and higher mitotic count and/or Ki67 labelling index. Despite appropriate surgery, the 5‐year survival rate for atypical carcinoids barely exceeds 50%–70%. The role of adjuvant therapy in lung carcinoids is not well‐defined, and clinical decisions are generally based on the presence of high‐risk features. Long‐term follow‐up is essential to monitor for recurrence, although the optimal follow‐up protocol remains unclear. To address the lack of consensus in clinical management decisions, the European Neuroendocrine Tumor Society (ENETS) initiated a survey among 20 expert centres. The survey identified varied opinions on approaches to imaging, surgery, use of adjuvant therapy, and follow‐up protocols. Notably, the absence of dedicated multidisciplinary lung neuroendocrine tumour boards in some centres was evident. Experts agreed on the need for a prospective adjuvant trial in high‐risk patients, emphasizing the feasibility of such a study. In conclusion, the study highlights the need for a more uniform adoption of existing guidelines in the management of lung carcinoid tumours and emphasizes the importance of international collaboration to advance research and patient care. Close collaboration between healthcare providers and patients is vital for effective long‐term surveillance and management of these rare tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoid TumorLung NeoplasmsNeuroendocrine TumorsHumansSurveys and QuestionnairesAdvisory CommitteesDisease Management

Stichwörter der Autor:innen

ENETSadjuvant treatmentlung carcinoidneuroendocrine tumoursurvey

Autor:innen und Institutionen

  • Hematology Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Rimini, Greece.
  • Department of General Surgery, Division of Thoracic Surgery, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Maimonides Biomedical Research Institute of Córdoba, University of Córdoba, Hospital Universitario Reina Sofía, Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), Córdoba,…
  • Rare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
  • Nuclear Medicine University Hospitals Leuven and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.

ORCID-Profile: Lisa Bodei, Clarisse Dromain, Beata Kos-Kudla, Anja Rinke, Thomas Walter

Förderung

  • World Health Organization

Zitieren

APA

Koumarianou, A., Filosso, P. L., Bodei, L., Castano, J. P., Fernandez-Cuesta, L., Deroose, C. M., Foll, M., Dromain, C., Reed, N. S., Caplin, M., Capdevila, J., Falkerby, J., Faggiano, A., Frilling, A., Grande, E., Hicks, R. J., Kasajima, A., Kos-Kudla, B., Krishna, B. A., …, & Walter, T. (2024). Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence ( CoE ): Survey from the ENETS lung NET task force. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13412

Vancouver

Koumarianou A, Filosso PL, Bodei L, Castano JP, Fernandez-Cuesta L, Deroose CM, et al. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence ( CoE ): Survey from the ENETS lung NET task force. Journal of Neuroendocrinology. 2024. doi:10.1111/jne.13412

BibTeX
@article{Koumarianou2024,
  author = {Koumarianou, Anna and Filosso, Pier Luigi and Bodei, Lisa and Castano, Justo P and Fernandez-Cuesta, Lynnette and Deroose, Christophe M and Foll, Matthieu and Dromain, Clarisse and Reed, Nicholas Simon and Caplin, Martyn and Capdevila, Jaume and Falkerby, Jenny and Faggiano, Antongiulio and Frilling, Andrea and Grande, Enrique and Hicks, Rodney J and Kasajima, Atsuko and Kos-Kudla, Beata and Krishna, B A and Lim, Eric and Rinke, Anja and Singh, Simron and Thirlwell, Chrissie and Volante, Marco and Walter, Thomas},
  title = {Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence ( CoE ): Survey from the ENETS lung NET task force},
  journal = {Journal of Neuroendocrinology},
  year = {2024},
  doi = {10.1111/jne.13412}
}
Kostenlos starten →